| Literature DB >> 34199184 |
Dariusz Walkowiak1, Bożena Mikołuć2, Renata Mozrzymas3, Łukasz Kałużny4, Bożena Didycz5, Dorota Korycińska-Chaaban6, Michał Patalan7, Joanna Jagłowska8, Agnieszka Chrobot9, Ewa Starostecka10, Joanna Zarębska11, Jarosław Walkowiak4.
Abstract
There is agreement that the pandemic has affected the healthcare system and behaviour of patients. This study aims to identify problems encountered by patients with phenylketonuria (PKU) and their parents/caregivers during the six-week pandemic lockdown in Poland (15 March to 30 April 2020). To determine the factors that influenced health and treatment-related issues, as well as the respondents' perception of the impact of the pandemic, study participants were asked to complete a non-validated online questionnaire comprising 31 questions (including 27 single-choice, two multiple-choice and two open-ended ones). A total of 571 patients or their parents completed the questionnaire, with 9.5% of respondents not performing any blood phenylalanine (Phe) test in the analysed period, 21.3% declaring a blood Phe increase, and 15.3% a decrease. Increased problems in contacting the doctor or dietitian were reported by 26.1% of subjects, whereas 39.3% of them felt restricted access to dietary products. Most (63.4%) participants were satisfied with remote contact with their PKU clinic. Better compliance was associated with higher odds of acceptance of remote contact and of reporting fewer problems with contacting the doctor, and with lower odds of missing Phe testing. Self-reported high stress was associated with higher odds of reporting the limited availability of low-Phe products and Phe-free formulas, as well as with increased Phe concentrations and non-PKU-related health problems. These patients also had poor dietary compliance and experienced more problems in contacting specialists. Health and treatment-related problems experienced during the pandemic lockdown were related to a higher intensity of stress in patient's family and worse therapy compliance before the pandemic. Previous experience of remote visits resulted in a better perception of this method of contact. It seems that this form of communication should be popularized and improved to increase therapy effectiveness in case of different limitations in the future. Special attention should be paid to vulnerable patients who may be at extra risk when the provision of standard care is affected.Entities:
Keywords: COVID-19 pandemic; PKU; compliance; phenylketonuria; remote medicine
Mesh:
Year: 2021 PMID: 34199184 PMCID: PMC8296241 DOI: 10.3390/ijerph18126399
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Respondents’ characteristics (N = 571).
| Characteristics | n/N (%) |
|---|---|
| Number of patients | 571 |
| Patient gender | |
| Female | 296 (51.8) |
| Male | 275 (48.2) |
| Mean age (SD) | 14.77 (12.6) |
| Age range | 0.17–53 |
| Missing age data | 4 (0.7) |
| Number of patients >26 years under parents’ supervision | 42 (7.4) |
| Questionnaire filled in by parents | 424 (74.3) |
| Questionnaire filled in by patients | 147 (25.7) |
| Quarantined | 11 (1.9) |
| Self-reported Phe levels before the pandemic | |
| As recommended | 363 (63.6) |
| Slightly too high | 174 (30.5) |
| Far too high | 34 (5.9) |
| Self-reported Phe levels during the pandemic lockdown | |
| Increased considerably | 27 (4.7) |
| Increased slightly | 95 (16.6) |
| Remained the same | 302 (52.9) |
| Decreased slightly | 75 (13.1) |
| Decreased considerably | 18 (3.2) |
| No tests in lockdown period | 54 (9.5) |
| Distance between household and the clinic | |
| In our city | 102 (17.9) |
| Less than 50 km | 112 (19.6) |
| 50–100 km | 128 (22.4) |
| More than 100 km | 229 (40.1) |
| Mode of travel to clinic | |
| Own car | 453 (79.3) |
| Rented car | 15 (2.6) |
| City transport | 45 (7.9) |
| Train or intercity bus | 45 (7.9) |
| Several trains or buses | 13 (2.3) |
| Travel time to doctor | |
| Less than 0.5 h | 105 (18.4) |
| 0.5–1 h | 153 (26.8) |
| 1–2 h | 174 (30.5) |
| 2–3 h | 91 (15.9) |
| More than 3 h | 48 (8.4) |
N—number of all respondents, n—number of a given answer, SD—standard deviation, Phe—phenylalanine.
The impact of contact frequency with a doctor before the pandemic on satisfaction with remote visits.
| Phone Contact Frequency | ||
|---|---|---|
| Group 1 (Patients with Regular Phone Contact with PKU Doctor/Dietitian before Pandemic) vs. Group 3 (Patients with Occasional/No Contact) | Group 2 (Patients with Several Phone Contacts with PKU Doctor/Dietitian before Pandemic) vs. Group 3 (Patients with Occasional/No Contact) | |
| Were you satisfied with the remote contact? | ||
| OR | 22.47 | 8.30 |
| 95% CI | 12.57–40.14 | 5.34–12.90 |
|
| <0.0001 | <0.0001 |
| Would you like to have remote contact in the future? | ||
| OR | 2.35 | 1.98 |
| 95% CI | 1.54–3.59 | 1.34–2.93 |
|
| <0.0001 | 0.0003 |
PKU—phenylketonuria, OR—odds ratio, CI—confidence interval.
The impact of travel time for a medical visit before the pandemic on satisfaction with remote visits.
| Travel Time to the Centre | ||
|---|---|---|
| How Long Does It Take to Get to Your Doctor? | ||
| >3 h to the Doctor vs. All Others | >2 h vs. <1 h | |
| OR | 2.17 | 1.77 |
| 95% CI | 1.19–3.96 | 1.17–2.69 |
|
| 0.0057 | 0.0037 |
OR—odds ratio, CI—confidence interval.
Self-reported Phe levels (normal vs. abnormal) before the pandemic and the perception of remote visits, availability of specialists and the lack of control Phe tests during the pandemic.
| Self-Reported Phe Levels (Normal vs. Abnormal) | ||||
|---|---|---|---|---|
| Satisfaction with Remote Contact | Problems in Contacting a Specialist | No Tests during the Pandemic | Positive Opinion on Remote Contact as a Means of Treating PKU | |
| OR | 1.56 | 0.59 | 0.42 | 1.68 |
| 95% CI | 1.10–2.22 | 0.40–0.87 | 0.24–0.76 | 1.10–2.56 |
|
| 0.0063 | 0.0034 | 0.0020 | 0.0080 |
PKU—phenylketonuria, OR—odds ratio, CI—confidence interval.
Comparison of patients’ frequency of reporting high stress vs. low-intermediate stress intensity depending on social interactions.
| Social Interactions (Declarations) | |||||
|---|---|---|---|---|---|
| Limited Low-Phe Product Availability | Limited Phe-Free Formula Availability | Worse Dietary Compliance | Need to Contact Other Parents/Patients | Problems in Contacting a Specialist | |
| OR | 2.00 | 1.87 | 2.03 | 1.97 | 1.55 |
| 95% CI | 1.42–2.84 | 1.24–2.64 | 1.24–3.35 | 1.22–3.19 | 1.06–0.27 |
|
| <0.0001 | <0.0001 | <0.0001 | 0.0028 | 0.0016 |
|
| |||||
|
|
| ||||
| OR | 1.95 | 3.67 | |||
| 95% CI | 1.23–3.10 | 1.75–7.69 | |||
|
| 0.0023 | 0.0003 | |||
Phe—phenylalanine, PKU—phenylketonuria, OR—odds ratio, CI—confidence interval.